JP2024502446A5 - - Google Patents

Info

Publication number
JP2024502446A5
JP2024502446A5 JP2023541058A JP2023541058A JP2024502446A5 JP 2024502446 A5 JP2024502446 A5 JP 2024502446A5 JP 2023541058 A JP2023541058 A JP 2023541058A JP 2023541058 A JP2023541058 A JP 2023541058A JP 2024502446 A5 JP2024502446 A5 JP 2024502446A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
composition according
compound
lung cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541058A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502446A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/011673 external-priority patent/WO2022150628A1/en
Publication of JP2024502446A publication Critical patent/JP2024502446A/ja
Publication of JP2024502446A5 publication Critical patent/JP2024502446A5/ja
Pending legal-status Critical Current

Links

JP2023541058A 2021-01-08 2022-01-07 癌の治療におけるkras g12c阻害剤の使用 Pending JP2024502446A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163135449P 2021-01-08 2021-01-08
US63/135,449 2021-01-08
US202163189625P 2021-05-17 2021-05-17
US63/189,625 2021-05-17
PCT/US2022/011673 WO2022150628A1 (en) 2021-01-08 2022-01-07 Use of a kras g12c inhibitor in treating cancers

Publications (2)

Publication Number Publication Date
JP2024502446A JP2024502446A (ja) 2024-01-19
JP2024502446A5 true JP2024502446A5 (cg-RX-API-DMAC7.html) 2025-01-15

Family

ID=80222156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541058A Pending JP2024502446A (ja) 2021-01-08 2022-01-07 癌の治療におけるkras g12c阻害剤の使用

Country Status (8)

Country Link
US (1) US20240091230A1 (cg-RX-API-DMAC7.html)
EP (2) EP4274579A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024502446A (cg-RX-API-DMAC7.html)
AU (1) AU2022205969A1 (cg-RX-API-DMAC7.html)
CA (1) CA3206523A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023007918A (cg-RX-API-DMAC7.html)
TW (1) TWI906448B (cg-RX-API-DMAC7.html)
WO (1) WO2022150628A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
PE20260006A1 (es) 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA127968C2 (uk) 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
EP3738593A1 (en) * 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
EP3972973A1 (en) 2019-05-21 2022-03-30 Amgen Inc. Solid state forms

Similar Documents

Publication Publication Date Title
JP2022009090A5 (cg-RX-API-DMAC7.html)
JP2024133475A5 (cg-RX-API-DMAC7.html)
JP2022537551A5 (cg-RX-API-DMAC7.html)
JP2024540015A5 (cg-RX-API-DMAC7.html)
CN114641293A (zh) 一种fgfr抑制剂的用途
CN103945849B (zh) 癌症的联合治疗
JP2024015120A5 (cg-RX-API-DMAC7.html)
JP2019532051A5 (cg-RX-API-DMAC7.html)
JP2019503365A5 (cg-RX-API-DMAC7.html)
CN101360495B (zh) 对癌症病人给药mTOR抑制剂
BRPI0915284B1 (pt) composição farmacêutica oral, e, uso de uma composição farmacêutica
JP2023548055A5 (cg-RX-API-DMAC7.html)
JP2023522716A5 (cg-RX-API-DMAC7.html)
JP2023546362A5 (cg-RX-API-DMAC7.html)
JP2021504384A5 (cg-RX-API-DMAC7.html)
CN103533940A (zh) 治疗晚期实体瘤的方法
WO2017118401A1 (zh) 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒
WO2015185011A1 (zh) 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物
JP2023522415A5 (cg-RX-API-DMAC7.html)
CN112584834B (zh) 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物
JP2022521173A5 (cg-RX-API-DMAC7.html)
TWI760306B (zh) 供治療癌症之口服投予紫杉醇及P-gp抑制劑的治療性組合
JP2004525143A5 (cg-RX-API-DMAC7.html)
JP2025509278A5 (cg-RX-API-DMAC7.html)
WO2008035461A1 (fr) Chimiothérapie adjuvante post-opératoire pour un cancer gastrique